40
Views
0
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Association of chronic divalproex sodium use and brain atrophy in Alzheimer’s disease

, , , , &
Pages 155-158 | Published online: 09 Jan 2014

References

  • Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. doi:10.1155/2010/479364 (2010) (Epub ahead of print).
  • Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell. Mol. Life Sci.64(16), 2090–2103 (2007).
  • Evans MD, Shinar R, Yaari R. Reversible dementia and gait disturbance after prolonged use of valproic acid. Seizure20(6), 509–511 (2011).
  • Abreu LN, Issler C, Lafer B. Valproate-induced reversible pseudoatrophy of the brain and hyperammonemic encephalopathy in a bipolar patient. Aust. N Z J. Psychiatry43(5), 484–485 (2009).
  • Adachi K, Utsumi Y, Kanaya A, Kimura S. Acute transient pseudoatrophy of the brain accompanying measles infection. Brain Dev.22(3), 193–195 (2000).
  • Guerrini R, Belmonte A, Canapicchi R, Casalini C, Perucca E. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia39(1), 27–32 (1998).
  • McLachlan RS. Pseudoatrophy of the brain with valproic acid monotherapy. Can. J. Neurol. Sci.14(3), 294–296 (1987).
  • Kidd SK, Schneider JS. Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Neuroscience194, 189–194 (2011).
  • Rouaux C, Panteleeva I, Rene F et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci.27(21), 5535–5545 (2007).
  • Dash PK, Orsi SA, Zhang M et al. Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS One5(6), e11383 (2010).
  • Fleisher AS, Truran D, Mai JT et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Alzheimer’s Disease Cooperative Study. Neurology77(13), 1263–1271 (2011).
  • Tariot PN, Schneider LS, Cummings J et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch. Gen. Psychiatry68(8), 853–861 (2011).
  • Jack CR Jr, Lowe VJ, Weigand SD et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain132(Pt 5), 1355–1365 (2009).
  • Scher AI, Xu Y, Korf ES et al. Hippocampal morphometry in population-based incident Alzheimer’s disease and vascular dementia: the HAAS. J. Neurol. Neurosurg. Psychiatry82(4), 373–376 (2011).
  • Scher AI, Xu Y, Korf ES et al. Hippocampal shape analysis in Alzheimer’s disease: a population-based study. Neuroimage36(1), 8–18 (2007).
  • Tsopelas C, Stewart R, Savva GM et al. Neuropathological correlates of late-life depression in older people. Br. J. Psychiatry198(2), 109–114 (2011).
  • Panza F, Frisardi V, Capurso C et al. Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am. J. Geriatr. Psychiatry18(2), 98–116 (2010).
  • Mendez MF. The accurate diagnosis of early-onset dementia. Int. J. Psychiatry Med.36(4), 401–412 (2006).
  • Shulman KI, Sykora K, Gill S et al. Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study. J. Clin. Psychiatry66(4), 424–427 (2005).
  • Monti B, Polazzi E, Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr. Mol. Pharmacol.2(1), 95–109 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.